相关实验视频

Updated: Jun 4, 2025

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

药物在阿尔茨海默病实验模型中重新使用

Sheer A Joodi¹, Weam W Ibrahim², Mahmoud M Khattab²

¹Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, ElKasr Elaini Street, Cairo, 11562, Egypt. sheeralaaa@gmail.com.

Inflammopharmacology

|January 3, 2025

概括

药物重新定位为阿尔茨海默病 (AD) 治疗提供了一个有前途的策略,解决了神经退行症和目前治疗方法未能解决的安全问题. 这种方法探索现有的药物,以开发有效的阿尔茨海默病治疗方法.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
药物开发药物开发

背景情况:

目前的阿尔茨海默病 (AD) 治疗只能提供症状缓解,不能阻止神经退行.
最近针对阿尔茨海默氏症的免疫疗法的安全性概况带来了重大挑战.

研究的目的:

突出药物重用作为开发新型AD疗法的战略的重要性.
审查AD病理生理学的生物变化和重新定位药物的潜力.

主要方法:

综合审查AD病理生理学,包括粉样和陶氏病理,氧化应激,神经炎症和信号通路.
对各种重新使用的药物 (抗炎,抗糖尿病等) 的分析. 在实验AD模型中.
对药物管道和FDA批准的AD药物的检查.

主要成果:

确定了与阿尔茨海默病相关的关键生物学途径,如粉样蛋白和病理,神经炎症和代谢失调.
在临床前AD模型中,在不同类别的药物中,重新定制药物的有希望的治疗潜力得到了证明.
审查了AD药物开发的现状,包括正在研究和已批准的疗法.

结论:

药物再利用为开发阿尔茨海默病有效治疗方法提供了可行和有前途的途径.
重用药物显示出显著的治疗活性,验证了AD治疗的药物重用策略.
对重定向药物的进一步研究可以加速对阿尔茨海默病的治愈治疗方法的开发.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.以及GSK-3ββ.Aβ42 Aβ42 Aβ42 Aβ42 Aβ42 Aβ42 Aβ42 Aβ42 Aβ42 这就是NF-κββ.Nrf2 没有任何问题在P38-MAPKK中使用.在mTOROR中使用mTOR.

更多相关视频

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...